Pfizer raises 2026 guidance after Q3, reports pipeline progress and new CFONov 3Quarterly updateBioNTech SEC4 Therapeutics, Inc.
Monte Rosa reports Phase 1 data for MRT-8102 in cardiovascular risk studyOct 1Clinical readoutMonte Rosa Therapeutics, Inc
Novartis starts Phase 2 trial of Monte Rosa's MRT-6160 in Sjögren's diseaseSep 8Clinical readoutMonte Rosa Therapeutics, IncNovartis
Monte Rosa reports Q2 2026 results as MGD pipeline advances on three frontsAug 6Quarterly updateMonte Rosa Therapeutics, Inc
Monte Rosa registers Phase 2 trial pairing MRT-2359 with apalutamide in prostate cancerAug 4Trial updateapalutamideMonte Rosa Therapeutics, Inc